Mackenzie Financial Corp Acquires Shares of 13,270 AngioDynamics, Inc. (NASDAQ:ANGO)

Mackenzie Financial Corp acquired a new stake in AngioDynamics, Inc. (NASDAQ:ANGO) in the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm acquired 13,270 shares of the medical instruments supplier’s stock, valued at approximately $80,000.

Several other large investors also recently bought and sold shares of ANGO. Millennium Management LLC grew its position in AngioDynamics by 41.9% in the second quarter. Millennium Management LLC now owns 1,793,454 shares of the medical instruments supplier’s stock valued at $10,850,000 after acquiring an additional 529,861 shares in the last quarter. Fund 1 Investments LLC acquired a new stake in AngioDynamics in the fourth quarter valued at approximately $3,896,000. Western Standard LLC grew its position in shares of AngioDynamics by 878.5% during the first quarter. Western Standard LLC now owns 523,393 shares of the medical instruments supplier’s stock worth $3,072,000 after buying an additional 469,906 shares in the last quarter. First Eagle Investment Management LLC acquired a new stake in shares of AngioDynamics during the second quarter worth approximately $1,321,000. Finally, Kennedy Capital Management LLC grew its position in shares of AngioDynamics by 425.0% during the first quarter. Kennedy Capital Management LLC now owns 190,236 shares of the medical instruments supplier’s stock worth $1,117,000 after buying an additional 154,002 shares in the last quarter. Institutional investors and hedge funds own 89.43% of the company’s stock.

AngioDynamics Price Performance

Shares of ANGO opened at $5.88 on Wednesday. The business’s fifty day moving average price is $7.41 and its 200 day moving average price is $6.65. AngioDynamics, Inc. has a 12-month low of $5.26 and a 12-month high of $8.25. The stock has a market capitalization of $235.52 million, a PE ratio of -1.21 and a beta of 0.65.

AngioDynamics (NASDAQ:ANGO) last announced its quarterly earnings data on Thursday, October 3rd. The medical instruments supplier reported ($0.11) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.15) by $0.04. AngioDynamics had a negative return on equity of 4.91% and a negative net margin of 61.55%. The firm had revenue of $67.50 million for the quarter, compared to analysts’ expectations of $67.93 million. During the same period last year, the business posted ($0.12) earnings per share. The firm’s revenue for the quarter was down 14.2% on a year-over-year basis. As a group, research analysts anticipate that AngioDynamics, Inc. will post -0.41 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of analysts have recently weighed in on ANGO shares. Canaccord Genuity Group decreased their price target on shares of AngioDynamics from $13.00 to $12.00 and set a “buy” rating for the company in a research report on Friday, October 4th. HC Wainwright reissued a “buy” rating and set a $14.00 price target on shares of AngioDynamics in a research report on Friday, October 4th.

Insider Buying and Selling

In other news, CEO James C. Clemmer acquired 20,000 shares of AngioDynamics stock in a transaction that occurred on Monday, October 7th. The shares were purchased at an average cost of $6.03 per share, for a total transaction of $120,600.00. Following the completion of the purchase, the chief executive officer now directly owns 681,582 shares of the company’s stock, valued at $4,109,939.46. This trade represents a 0.00 % increase in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. 5.10% of the stock is currently owned by company insiders.

AngioDynamics Profile

AngioDynamics, Inc, a medical technology company, engages in the design, manufacture, and sale of medical, surgical, and diagnostic devices for the use in treating peripheral vascular disease, and oncology and surgical settings in the United States and internationally. The company offers Auryon Atherectomy system that is designed to deliver an optimized wavelength, pulse width, and amplitude to remove lesions while preserving vessel wall endothelium.